24249435Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain MCancerAngiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Transitional Cell; Indoles; Pyrroles; Urologic Neoplasms; Vascular Endothelial Growth Factor Receptor-2Adult; Aged; Confounding Factors, Epidemiologic; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Sample Size; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor ADouble-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014 Mar 01; 120(5):692-701.Cancer2013-11-18T00:00:002013Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000368Living Beings1341183530.294764AgedD000328Living Beings1578255770.254432AdultD000970Chemicals & Drugs40723510.435461Antineoplastic AgentsD002295Disorders601640.861916Carcinoma, Transitional CellD004311Procedures33818220.708936Double-Blind MethodD007211Chemicals & Drugs1343180.849938IndolesD008875Concepts & IdeasLiving Beings1473249570.258811Middle AgedD005260Physiology1992444050.191167FemaleD006801Living Beings2262862810.130052HumansD014571Disorders28770.914227Urologic NeoplasmsD008297Physiology1931408600.201617MaleD016896Concepts & Ideas101179490.402389Treatment OutcomeD018401Concepts & Ideas831300.942907Sample SizeD018450Physiology49815310.700842Disease ProgressionD020533Chemicals & DrugsPhysiology1073090.812499Angiogenesis InhibitorsD040301Chemicals & Drugs46810.964165Vascular Endothelial Growth Factor Receptor-2D011758Chemicals & Drugs621840.890788PyrrolesD057239Procedures14200.991669Early Termination of Clinical TrialsD042461Chemicals & Drugs1564070.844293Vascular Endothelial Growth Factor AD053208Concepts & Ideas3258590.818599Kaplan-Meier EstimateAuthorship 6451850.1219420.1219421authors10.2522has subject areaD004334Concepts & Ideas2609160.852414Drug Administration ScheduleD018572Concepts & Ideas25812030.792696Disease-Free SurvivalMedicineUniversity of ChicagoWalter M.StadlerWalter M. Stadler41.78927490000000-87.601250000000001904Stadler, Walter M.Professortrue1ProfessorProfessor